XB-628

N/A

Report date: 2025/05/15 20:00:08

Base Information

Drug NameXB-628
Drug Alias NameXB628
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-NK cell lectin-like receptor subfamily C member 1
TargetsProgrammed death-ligand 1NK cell lectin-like receptor subfamily C member 1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesExelixis Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A